VQ Biomedical is a technology company.
VQ Biomedical has raised $2.0M across 1 funding round.
VQ Biomedical has raised $2.0M in total across 1 funding round.
VQ Biomedical has raised $2.0M in total across 1 funding round.
VQ Biomedical's investors include 7BC Venture Capital, Audrey Capital, Bain Capital, Bold Capital Partners, Preston-Werner Ventures, Safar Partners, Samsung NEXT Ventures, The Hit Forge, Bob Young, Tobias Lutke.
VQ Biomedical is a medical device startup developing a minimally invasive central venous catheter that delivers supplemental oxygen directly into the bloodstream for patients with acute respiratory distress syndrome (ARDS) and severe lung injuries.[1][2][4] It serves critically ill hospitalized patients, addressing limitations of mechanical ventilation and ECMO by enabling lung rest and healing without invasive blood pumping, while reducing costs and staffing needs for payors.[1][2] The company shows early growth momentum as a seed-stage innovator backed by Tiny Tech Fund, with experienced leadership advancing toward FDA clearance.[1][2]
The technology originated from an unmet clinical need identified by Dr. Straube during his critical care training at Duke University Hospital, leading to the development of an intravascular oxygenation catheter.[2] VQ Biomedical was co-founded by CEO Galen Robertson, who brings over 20 years of experience launching medical devices, including as COO and co-founder of 410 Medical for critical care infusion devices; he has guided 12 devices through FDA 510(k) processes and holds 90 patents.[2] VP of R&D Pat Sterlina complements this with 20+ years in medtech, spanning implantable devices, robotics, and regulatory affairs.[2] Early traction stems from Duke's innovation ecosystem, positioning it as a seed-stage company focused on respiratory failure solutions.[1][4]
VQ Biomedical rides the wave of advancing respiratory care technologies, amplified by lessons from COVID-19 highlighting ARDS treatment gaps and demand for less invasive critical care options.[2] Timing aligns with post-pandemic focus on cost-efficient alternatives to ECMO, amid rising ICU pressures and medtech innovation in intravascular therapies.[1][3] Market forces like aging populations, chronic lung diseases, and payer demands for lower-cost interventions favor its model, while Duke's ecosystem boosts credibility in the startup landscape.[4] It influences the field by pioneering bedside oxygenation, potentially bridging gaps between ventilation and full ECMO for broader hospital adoption.[2]
VQ Biomedical is poised for FDA milestones and clinical trials, leveraging its team's regulatory prowess to scale from seed to market entry amid growing respiratory tech demand.[2] Trends like AI-enhanced critical care and minimally invasive devices will shape its path, expanding applications beyond ARDS to other lung failures. Its influence could evolve by setting a new standard for affordable oxygenation, transforming outcomes in overwhelmed ICUs and reinforcing medtech's role in accessible innovation—echoing its origins in identifying critical unmet needs.[1][2]
VQ Biomedical has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in March 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2025 | $2.0M Seed | 7BC Venture Capital, Audrey Capital, Bain Capital, Bold Capital Partners, Preston-Werner Ventures, Safar Partners, Samsung NEXT Ventures, The Hit Forge, Bob Young, Tobias Lutke |